Heinz‐Gert Höffkes

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · JAMA Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Surgery +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial

Ulrich Dührsen, Stefan Müller, Bernd Hertenstein et al. · Journal of Clinical Oncology · 2018 · 251 citations · Full text

Medicine, Oncology, Chemotherapy +14

Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype

Claudia Haferlach, Tamara Alpermann, Susanne Schnittger et al. · Blood · 2011 · 66 citations · Full text

Life Sciences, Hematology, Oncology +17